NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GW Pharmaceuticals PLC- Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $96.33 -1.32 (-1.35 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$96.02Now: $96.33▼$100.7650-Day Range$72.48MA: $94.39▼$128.5652-Week Range$67.98Now: $96.33▼$196.00Volume439,238 shsAverage Volume609,605 shsMarket Capitalization$2.98 billionP/E RatioN/ADividend YieldN/ABeta2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingGW Pharmaceuticals PLC- has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $193.00, GW Pharmaceuticals PLC- has a potential upside of 100.3% from its current price of $96.37.Amount of Analyst CoverageGW Pharmaceuticals PLC- has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesGW Pharmaceuticals PLC- has received 794 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGW Pharmaceuticals PLC- has received 525 “underperform” votes. (Add your “underperform” vote.)Community SentimentGW Pharmaceuticals PLC- has received 60.20% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote “Outperform” if you believe GWPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGW Pharmaceuticals PLC- does not currently pay a dividend.Dividend GrowthGW Pharmaceuticals PLC- does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GW Pharmaceuticals PLC- insiders have sold 25,744.50% more of their company's stock than they have bought. Specifically, they have bought $48,960.00 in company stock and sold $12,653,466.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of GW Pharmaceuticals PLC- is held by insiders.Percentage Held by Institutions80.70% of the stock of GW Pharmaceuticals PLC- is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GW Pharmaceuticals PLC- are expected to decrease by -383.96% in the coming year, from ($1.87) to $5.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GW Pharmaceuticals PLC- is -209.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GW Pharmaceuticals PLC- is -209.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGW Pharmaceuticals PLC- has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GWPH Previous Symbol CUSIPN/A CIK1351288 Webhttp://www.gwpharm.com/ Phone44-12-2326-6800Debt Debt-to-Equity Ratio0.04 Current Ratio5.95 Quick Ratio5.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$311.33 million Price / Sales9.57 Cash Flow$0.01 per share Price / Cash Flow12,833.36 Book Value$23.48 per share Price / Book4.10Profitability EPS (Most Recent Fiscal Year)($0.24) Net Income$-9,020,000.00 Net Margins-2.90% Return on Equity-16.12% Return on Assets-13.65%Miscellaneous Employees791 Outstanding Shares30,920,000Market Cap$2.98 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive GWPH News and Ratings via Email Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GWPH Rates by TradingView GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions How has GW Pharmaceuticals PLC-'s stock been impacted by COVID-19 (Coronavirus)? GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GWPH stock has increased by 10.9% and is now trading at $96.37. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-. When is GW Pharmaceuticals PLC-'s next earnings date? GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for GW Pharmaceuticals PLC-. How were GW Pharmaceuticals PLC-'s earnings last quarter? GW Pharmaceuticals PLC- (NASDAQ:GWPH) posted its earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.32. The biopharmaceutical company had revenue of $109.10 million for the quarter, compared to the consensus estimate of $80.92 million. GW Pharmaceuticals PLC- had a negative net margin of 2.90% and a negative return on equity of 16.12%. GW Pharmaceuticals PLC-'s revenue for the quarter was up 1528.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.20) earnings per share. View GW Pharmaceuticals PLC-'s earnings history. What price target have analysts set for GWPH? 14 brokerages have issued 12-month price targets for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $128.00 to $260.00. On average, they expect GW Pharmaceuticals PLC-'s stock price to reach $193.00 in the next year. This suggests a possible upside of 100.3% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-. Has GW Pharmaceuticals PLC- been receiving favorable news coverage? Media headlines about GWPH stock have trended very negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutGW Pharmaceuticals PLC-. Are investors shorting GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC- saw a decline in short interest in February. As of February 28th, there was short interest totaling 5,250,000 shares, a decline of 6.9% from the February 13th total of 5,640,000 shares. Based on an average trading volume of 609,800 shares, the days-to-cover ratio is presently 8.6 days. Approximately 17.1% of the company's stock are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain. Who are some of GW Pharmaceuticals PLC-'s key competitors? Some companies that are related to GW Pharmaceuticals PLC- include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). What other stocks do shareholders of GW Pharmaceuticals PLC- own? Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Intel (INTC) and Zynerba Pharmaceuticals (ZYNE). Who are GW Pharmaceuticals PLC-'s key executives? GW Pharmaceuticals PLC-'s management team includes the following people: Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)Mr. Justin D. Gover, CEO & Exec. Director (Age 48)Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61) What is GW Pharmaceuticals PLC-'s stock symbol? GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH." Who are GW Pharmaceuticals PLC-'s major shareholders? GW Pharmaceuticals PLC-'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (2.62%) and Investors Financial Group LLC (0.02%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-. Which major investors are selling GW Pharmaceuticals PLC- stock? GWPH stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd.. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz, and William A Waldegrave. View insider buying and selling activity for GW Pharmaceuticals PLC-. Which major investors are buying GW Pharmaceuticals PLC- stock? GWPH stock was purchased by a variety of institutional investors in the last quarter, including Investors Financial Group LLC. View insider buying and selling activity for GW Pharmaceuticals PLC-. How do I buy shares of GW Pharmaceuticals PLC-? Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GW Pharmaceuticals PLC-'s stock price today? One share of GWPH stock can currently be purchased for approximately $96.37. How big of a company is GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC- has a market capitalization of $2.98 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. View additional information about GW Pharmaceuticals PLC-. What is GW Pharmaceuticals PLC-'s official website? The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/. How can I contact GW Pharmaceuticals PLC-? GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Investment (ROI)?
